- Home
- DRMA vs ELAB Comparison
DRMA vs ELAB Comparison
Compare DRMA & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- ELAB
- Stock Information
- Founded
- DRMA 2014
- ELAB 2020
- Country
- DRMA United States
- ELAB United States
- Employees
- DRMA N/A
- ELAB N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- ELAB
- Sector
- DRMA Health Care
- ELAB
- Exchange
- DRMA Nasdaq
- ELAB Nasdaq
- Market Cap
- DRMA 3.6M
- ELAB 3.2M
- IPO Year
- DRMA 2021
- ELAB 2023
- Fundamental
- Price
- DRMA $5.99
- ELAB $5.70
- Analyst Decision
- DRMA Strong Buy
- ELAB
- Analyst Count
- DRMA 1
- ELAB 0
- Target Price
- DRMA $10.00
- ELAB N/A
- AVG Volume (30 Days)
- DRMA 32.3K
- ELAB 2.4M
- Earning Date
- DRMA 11-12-2025
- ELAB 11-13-2025
- Dividend Yield
- DRMA N/A
- ELAB N/A
- EPS Growth
- DRMA N/A
- ELAB N/A
- EPS
- DRMA N/A
- ELAB N/A
- Revenue
- DRMA N/A
- ELAB N/A
- Revenue This Year
- DRMA N/A
- ELAB N/A
- Revenue Next Year
- DRMA N/A
- ELAB N/A
- P/E Ratio
- DRMA N/A
- ELAB N/A
- Revenue Growth
- DRMA N/A
- ELAB N/A
- 52 Week Low
- DRMA $5.04
- ELAB $4.29
- 52 Week High
- DRMA $24.90
- ELAB $1,817.54
- Technical
- Relative Strength Index (RSI)
- DRMA 54.71
- ELAB 48.35
- Support Level
- DRMA $5.27
- ELAB $4.29
- Resistance Level
- DRMA $5.74
- ELAB $4.89
- Average True Range (ATR)
- DRMA 0.40
- ELAB 0.56
- MACD
- DRMA 0.07
- ELAB 0.08
- Stochastic Oscillator
- DRMA 80.17
- ELAB 46.96
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.